From bench to bedside: Advancements in urological oncology.
作者信息
Niu Shaoxi, Zhang Yaoguang, Huang Hai, Ma Xin
机构信息
Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing 100143, China.
Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
出版信息
Cancer Pathog Ther. 2024 Sep 11;3(4):278-279. doi: 10.1016/j.cpt.2024.09.004. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
From bench to bedside: Advancements in urological oncology.
Cancer Pathog Ther. 2024 Sep 11;3(4):278-279. doi: 10.1016/j.cpt.2024.09.004. eCollection 2025 Jul.
2
Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care.
Oncol Res Treat. 2025;48(1-2):4-13. doi: 10.1159/000542458. Epub 2024 Nov 7.
3
Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research.
Clin Cancer Res. 2024 Jul 15;30(14):2905-2909. doi: 10.1158/1078-0432.CCR-23-2570.
4
National and Location-Specific Medicare Physician Fee Reimbursement Trends in Urologic Oncology From 2002 to 2024.
Urol Pract. 2025 Jul;12(4):380-390. doi: 10.1097/UPJ.0000000000000795. Epub 2025 Mar 5.
5
Exploring Experimental Models of Colorectal Cancer: A Critical Appraisal from 2D Cell Systems to Organoids, Humanized Mouse Avatars, Organ-on-Chip, CRISPR Engineering, and AI-Driven Platforms-Challenges and Opportunities for Translational Precision Oncology.
Cancers (Basel). 2025 Jun 26;17(13):2163. doi: 10.3390/cancers17132163.
6
Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.
J Adv Res. 2025 Jun 12. doi: 10.1016/j.jare.2025.06.009.
7
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.
Urol Oncol. 2015 Jun;33(6):269. doi: 10.1016/j.urolonc.2015.01.026. Epub 2015 Mar 26.
8
MicroRNA-145 in urologic tumors: biological roles, regulatory networks, and clinical translation.
Front Pharmacol. 2025 Jul 4;16:1609646. doi: 10.3389/fphar.2025.1609646. eCollection 2025.
9
Quality Indicators in the Clinical Specialty of Urology: A Systematic Review.
Eur Urol Focus. 2023 May;9(3):435-446. doi: 10.1016/j.euf.2022.12.004. Epub 2022 Dec 26.
10
The reporting quality of randomised controlled trials in surgery: a systematic review.
Int J Surg. 2007 Dec;5(6):413-22. doi: 10.1016/j.ijsu.2007.06.002. Epub 2007 Oct 29.
本文引用的文献
1
Integrative analysis of cuproptosis-related lncRNAs: Unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer.
Cancer Pathog Ther. 2024 Mar 29;3(1):48-59. doi: 10.1016/j.cpt.2024.03.004. eCollection 2025 Jan.
2
Three-dimensional (3D) augmented reality during Retzius-sparing robot-assisted radical prostatectomy (RS-RARP): First experience.
Cancer Pathog Ther. 2024 Jun 20;3(1):81-84. doi: 10.1016/j.cpt.2024.06.003. eCollection 2025 Jan.
3
Chimeric RNAs and their implication in prostate cancer.
Cancer Pathog Ther. 2023 May 1;1(3):216-219. doi: 10.1016/j.cpt.2023.04.003. eCollection 2023 Jul.
4
Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.
Cancer Pathog Ther. 2022 Dec 24;1(3):195-204. doi: 10.1016/j.cpt.2022.12.003. eCollection 2023 Jul.
5
Epidemiology and Prevention of Prostate Cancer.
Eur Urol Oncol. 2021 Dec;4(6):877-892. doi: 10.1016/j.euo.2021.09.006. Epub 2021 Oct 26.
Zotero 插件